Timber Pharmaceuticals (TMBR) Stock Price, News & Analysis

Company Overview

Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.34 to $2.94
• 52-Week Range: N/A
• Volume: 26,307 shs
• Average Volume: 511,937 shs
• Market Capitalization: $1.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TMBR Stock Analysis - Frequently Asked Questions

When did Timber Pharmaceuticals' stock split?

Shares of Timber Pharmaceuticals reverse split before market open on Wednesday, November 9th 2022. The 1-50 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Timber Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Timber Pharmaceuticals investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Castor Maritime (CTRM) and Phunware (PHUN).

Company Calendar

• Today: 11/23/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NYSE:TMBR
• CUSIP: N/A
• CIK: 1504167
• Web: www.timberpharma.com
• Phone: (973) 314-9577
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-19,380,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -511.45%
• Return on Assets: -180.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.50
• Quick Ratio: 0.50

Sales & Book Value

• Annual Sales: $80,000.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.79 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 3,430,000
• Free Float: 3,378,000
• Market Cap: $1.21 million
• Optionable: Not Optionable
• Beta: 0.03